Brainstorm Cell Therapeutics Inc
BCLI1.170USD
0.0000.00%
Fechamento 02/06, 16:00（ET）Cotações atrasadas em 15 min
9.26MValor de mercado
PerdaP/L TTM
Mais detalhes de Brainstorm Cell Therapeutics Inc Empresa
BrainStorm Cell Therapeutics Inc. is a developer of autologous adult stem cell therapeutics for debilitating neurodegenerative diseases. The neurodegenerative diseases include Amyotrophic Lateral Sclerosis (ALS), Progressive Multiple Sclerosis (PMS), Alzheimer’s disease (AD), and others. The Company is engaged in the clinical development and commercialization of the NurOwn technology platform used to produce autologous mesenchymal stem cells- neurotrophic factors (MSC-NTF) cells. NurOwn leverages cell culture methods to induce autologous bone marrow derived MSCs to secrete high levels of NTFs, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival and improve neurological function. Autologous MSC-NTF cells is for the treatment of ALS. It has completed a phase III trial in ALS. Its wholly owned subsidiary, BrainStorm Cell Therapeutics Ltd., holds exclusive rights to commercialize NurOwn technology.
Informações de Brainstorm Cell Therapeutics Inc
Código da empresaBCLI
Nome da EmpresaBrainstorm Cell Therapeutics Inc
Data de listagemMay 28, 2003
CEOMr. Chaim Lebovits
Número de funcionários27
Tipo de títulosOrdinary Share
Fim do ano fiscalMay 28
Endereço1325 Avenue Of Americas
CidadeNEW YORK
Bolsa de valoresUS 'Other OTC' and Grey Market
PaísUnited States of America
Código postal10019
Telefone12014880460
Sitehttps://brainstorm-cell.com/
Código da empresaBCLI
Data de listagemMay 28, 2003
CEOMr. Chaim Lebovits
Executivos da empresa Brainstorm Cell Therapeutics Inc
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Uri Yablonka
Mr. Uri Yablonka
Director, Executive Vice President, Chief Business Officer, Secretary
Director, Executive Vice President, Chief Business Officer, Secretary
68.46K
--
Dr. Hartoun Hartounian, Ph.D.
Dr. Hartoun Hartounian, Ph.D.
Executive Vice President, Chief Operating Officer
Executive Vice President, Chief Operating Officer
52.00K
--
Ms. Alla Patlis, CPA
Ms. Alla Patlis, CPA
Interim Chief Financial Officer, Controller
Interim Chief Financial Officer, Controller
44.35K
+919.54%
Dr. Stacy R. Lindborg, Ph.D.
Dr. Stacy R. Lindborg, Ph.D.
Director
Director
44.15K
--
Dr. Irit Arbel, Ph.D.
Dr. Irit Arbel, Ph.D.
Independent Vice Chairman of the Board
Independent Vice Chairman of the Board
41.05K
--
Mr. Nir Naor, CPA
Mr. Nir Naor, CPA
Independent Director
Independent Director
31.47K
+3833.25%
Dr. Ibrahim B. (Bob) Dagher, M.D.
Dr. Ibrahim B. (Bob) Dagher, M.D.
Executive Vice President, Chief Medical Officer
Executive Vice President, Chief Medical Officer
--
--
Prof. Jacob A. Frenkel, Ph.D.
Prof. Jacob A. Frenkel, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Menghisteab (Menghis) Bairu, M.D.
Dr. Menghisteab (Menghis) Bairu, M.D.
Independent Director
Independent Director
--
--
Dr. Anthony John (Tony) Polverino, Ph.D.
Dr. Anthony John (Tony) Polverino, Ph.D.
Independent Director
Independent Director
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Uri Yablonka
Mr. Uri Yablonka
Director, Executive Vice President, Chief Business Officer, Secretary
Director, Executive Vice President, Chief Business Officer, Secretary
68.46K
--
Dr. Hartoun Hartounian, Ph.D.
Dr. Hartoun Hartounian, Ph.D.
Executive Vice President, Chief Operating Officer
Executive Vice President, Chief Operating Officer
52.00K
--
Ms. Alla Patlis, CPA
Ms. Alla Patlis, CPA
Interim Chief Financial Officer, Controller
Interim Chief Financial Officer, Controller
44.35K
+919.54%
Dr. Stacy R. Lindborg, Ph.D.
Dr. Stacy R. Lindborg, Ph.D.
Director
Director
44.15K
--
Dr. Irit Arbel, Ph.D.
Dr. Irit Arbel, Ph.D.
Independent Vice Chairman of the Board
Independent Vice Chairman of the Board
41.05K
--
Mr. Nir Naor, CPA
Mr. Nir Naor, CPA
Independent Director
Independent Director
31.47K
+3833.25%
Detalhamento da receita
Os dados relevantes ainda não foram divulgados pela empresa.
Os dados relevantes ainda não foram divulgados pela empresa.
Por Empresa
Por Região
Os dados relevantes ainda não foram divulgados pela empresa.
Distribuição de ações
Atualizado em: há 16 horas
Atualizado em: há 16 horas
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Ruck (Matthew J)
2.50%
Lebovits Chaim
1.82%
ACC International Holdings, Ltd.
1.21%
Dagher (Ibrahim B.)
0.72%
Yablonka (Uri)
0.62%
Outro
93.13%
Investidores
Investidores
Proporção
Ruck (Matthew J)
2.50%
Lebovits Chaim
1.82%
ACC International Holdings, Ltd.
1.21%
Dagher (Ibrahim B.)
0.72%
Yablonka (Uri)
0.62%
Outro
93.13%
Tipos de investidores
Investidores
Proporção
Individual Investor
8.44%
Holding Company
1.21%
Investment Advisor
0.02%
Outro
90.33%
Participação acionária institucional
Atualizado em: qui, 1 de jan
Atualizado em: qui, 1 de jan
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q4
81
2.42K
0.02%
-1.20M
2025Q3
92
137.97K
1.25%
-1.09M
2025Q2
115
2.33M
29.32%
+762.13K
2025Q1
116
2.29M
28.90%
+743.86K
2024Q4
114
1.19M
21.02%
-226.10K
2024Q3
109
1.22M
22.61%
-265.31K
2024Q2
109
1.32M
25.54%
+439.02K
2024Q1
108
855.32K
19.26%
-132.87K
2023Q4
109
841.70K
26.44%
-125.02K
2023Q3
116
902.82K
33.14%
-178.28K
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Ruck (Matthew J)
275.84K
2.5%
+275.84K
--
Nov 13, 2024
Lebovits Chaim
200.96K
1.82%
--
--
Apr 01, 2025
ACC International Holdings, Ltd.
133.39K
1.21%
--
--
Apr 01, 2025
Dagher (Ibrahim B.)
79.52K
0.72%
--
--
Apr 01, 2025
Yablonka (Uri)
68.46K
0.62%
--
--
Apr 01, 2025
Hartounian (Hartoun)
52.00K
0.47%
--
--
Apr 01, 2025
Patlis (Alla)
44.35K
0.4%
+40.00K
+919.54%
Jan 01, 2025
Lindborg (Stacy R)
44.15K
0.4%
--
--
Apr 01, 2025
Frenkel (Jacob A.)
43.78K
0.4%
--
--
Apr 01, 2025
Arbel (Irit)
41.05K
0.37%
--
--
Apr 01, 2025
Ver Mais
ETFs Relacionados
Atualizado em: sáb, 6 de dez
Atualizado em: sáb, 6 de dez
Nome
Proporção
iShares Micro-Cap ETF
0%
iShares Micro-Cap ETF
Proporção0%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Data ex-dividendo
Tipo
Proporção
Sep 26, 2024
Merger
15→1
Sep 26, 2024
Merger
15→1
Sep 26, 2024
Merger
15→1
Sep 26, 2024
Merger
15→1
Data
Data ex-dividendo
Tipo
Proporção
Sep 26, 2024
Merger
15→1
Sep 26, 2024
Merger
15→1
Sep 26, 2024
Merger
15→1
Sep 26, 2024
Merger
15→1
